deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02824029

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Classical Hodgkin Lymphoma Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma
Interventions Ibrutinib Laboratory Biomarker Analysis Pharmacological Study
Updated 14 times since 2017 Last updated: Jan 27, 2025 Started: Jun 30, 2016 Primary completion: May 12, 2023 Completion: Jan 8, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Classical Hodgkin Lymphoma and Recurrent Hodgkin Lymphoma and is currently completed. Barbara Ann Karmanos Cancer Institute leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Nov 2021 · 7 months · monthly snapshot~Nov 2021 – ~Jul 2022 · 8 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 17 months · monthly snapshot

Change History

14 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Apr 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  5. Mar 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  7. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barbara Ann Karmanos Cancer Institute
  • National Cancer Institute (NCI)
Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations